Willis Investment Counsel Buys 19,192 Shares of Medtronic PLC $MDT

Willis Investment Counsel lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 401,868 shares of the medical technology company’s stock after purchasing an additional 19,192 shares during the period. Medtronic accounts for 2.1% of Willis Investment Counsel’s holdings, making the stock its 11th biggest position. Willis Investment Counsel’s holdings in Medtronic were worth $38,274,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC raised its position in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC increased its stake in shares of Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the period. Wealthcare Advisory Partners LLC increased its position in Medtronic by 17.3% during the 2nd quarter. Wealthcare Advisory Partners LLC now owns 9,094 shares of the medical technology company’s stock worth $793,000 after buying an additional 1,343 shares during the period. SteelPeak Wealth LLC acquired a new stake in Medtronic in the 2nd quarter worth about $218,000. Finally, REAP Financial Group LLC boosted its stake in shares of Medtronic by 69.8% in the second quarter. REAP Financial Group LLC now owns 769 shares of the medical technology company’s stock valued at $67,000 after buying an additional 316 shares during the period. 82.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on MDT shares. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Truist Financial lowered their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Finally, William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average price target of $110.67.

Medtronic Stock Performance

MDT opened at $102.64 on Friday. The company has a market cap of $131.59 billion, a price-to-earnings ratio of 27.62, a PEG ratio of 2.68 and a beta of 0.71. The company’s fifty day moving average price is $99.44 and its two-hundred day moving average price is $96.01. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s payout ratio is 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).